Younger DCIS Patients Face Higher Recurrence Risk After Breast-Conserving Surgery

Article

Following breast-conserving surgery for ductal carcinoma in situ (DCIS), younger women face a higher risk than older patients for recurrence of both DCIS and invasive carcinomas.

Following breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS), younger women face a higher risk than older patients for recurrence of both DCIS and invasive carcinomas, reported Kimberly Van Zee, MD, FACS, a surgical oncologist at Memorial Sloan Kettering Cancer Center in New York, at the 33rd Annual Miami Breast Cancer Conference, held March 10–13 in Miami Beach, Florida.

“Young age (younger than age 40 years at diagnosis) is a highly significant risk factor for any recurrence after BCS for DCIS,” Dr. Van Zee said, during her review of the available research.

Ten-year recurrence rates of 27.3% for women younger than 40 vs 7.5% among women 80 or older,” she said. “This age effect persists even after adjusting for other factors that vary by age.”

“Older age was associated with lower recurrence in both cohorts that did and did not receive radiation,” she added.

Women younger than 40 years face a seven-fold higher risk of invasive recurrence than do women age 80 or older at the time of DCIS diagnosis.

“In women younger than 40 years, invasive recurrences are more likely than DCIS recurrences,” she noted, whereas DCIS recurrences are more common in women age 40 or older.

“Age is an important factor that should be considered in weighing the various treatment options, including surgical options and the use of adjuvant radiation and endocrine therapies,” Dr. Van Zee said. “Women age 80 or older are at low risk of recurrence, even in the absence of adjuvant therapies.”

Recent Videos
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Related Content